Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction

被引：24

作者：

Chehal, MK ^{[1
]}

Granville, DJ ^{[1
]}

机构：

[1] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada

来源：

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY | 2006年 / 84卷 / 01期

关键词：

cytochrome p450 enzymes; endothelium; vascular dysfunction; myocardial infarction; ischemia; reperfusion; heart attack; atherosclerosis; oxidative stress; reactive oxygen species; superoxide;

D O I：

10.1139/y05-139

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The cytochrome p450 2C (CYP2C) monooxygenase family is a key player in the generation of epoxyeicosairienoic acids. It has recently become apparent that CYP plays an important role in cardiovascular physiology and contributes to the pathogenesis of various cardiovascular diseases. In particular, several Studies have demonstrated it role for these enzymes in cardiac ischemia and reperfusion injury. The current review summarizes the role of the CYP epoxygenase, CYP2C9, in ischemic heart disease and vascular homeostasis.

引用

收藏

页码：15 / 20

页数：6

相关论文

共 45 条

[11] NITRIC-OXIDE DECREASES CYTOKINE-INDUCED ENDOTHELIAL ACTIVATION - NITRIC-OXIDE SELECTIVELY REDUCES ENDOTHELIAL EXPRESSION OF ADHESION MOLECULES AND PROINFLAMMATORY CYTOKINES [J].

DECATERINA, R ;

LIBBY, P ;

PENG, HB ;

THANNICKAL, VJ ;

RAJAVASHISTH, TB ;

GIMBRONE, MA ;

SHIN, WS ;

LIAO, JK .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :60-68

[12] Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].

Dickmann, LJ ;

Rettie, AE ;

Kneller, MB ;

Kim, RB ;

Wood, AJJ ;

Stein, CM ;

Wilkinson, GR ;

Schwarz, UI .

MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387

[13] Cytochrome P-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia [J].

Earley, S ;

Pastuszyn, A ;

Walker, BR .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 285 (01) :H127-H136

[14] Inhibition of cytochrome P4502C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease [J].

Fichtlscherer, S ;

Dimmeler, S ;

Breuer, S ;

Busse, R ;

Zeiher, AM ;

Fleming, I .

CIRCULATION, 2004, 109 (02) :178-183

[15] Cytochrome P4502C is an EDHF synthase in coronary arteries [J].

Fisslthaler, B ;

Popp, R ;

Kiss, L ;

Potente, M ;

Harder, DR ;

Fleming, I ;

Busse, R .

NATURE, 1999, 401 (6752) :493-497

[16] Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP2C expression [J].

Fisslthaler, B ;

Michaelis, UR ;

Randriamboavonjy, V ;

Busse, R ;

Fleming, I .

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2003, 1619 (03) :332-339

[17] Cytochrome P450 epoxygenases as EDHF synthase(s) [J].

Fleming, I .

PHARMACOLOGICAL RESEARCH, 2004, 49 (06) :525-533

[18] The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells [J].

Fleming, I ;

Fisslthaler, B ;

Michaelis, UR ;

Kiss, L ;

Popp, R ;

Busse, R .

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2001, 442 (04) :511-518

[19] Endothelium-derived hyperpolarizing factor synthase (cytochrome P4502C9) is a functionally significant source of reactive oxygen species in coronary arteries [J].

Fleming, I ;

Michaelis, UR ;

Bredenkötter, D ;

Fisslthaler, B ;

Dehghani, F ;

Brandes, RP ;

Busse, R .

CIRCULATION RESEARCH, 2001, 88 (01) :44-51

[20] Cytochrome P450 enzymes in vascular homeostasis [J].

Fleming, I .

CIRCULATION RESEARCH, 2001, 89 (09) :753-762

← 1 2 3 4 5 →